shutterstock_1493291597-med_edited.jpg

CALMING THE CYTOKINE STORM

REBALANCING THE IMMUNE SYSTEM

INNOVATIVE TREATMENT FOR AN OVERREACTIVE IMMUNE SYSTEM

 

CytoAgents is a clinical-stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need, including oncology CAR-T cell therapy, COVID-19, and respiratory epidemics.

 

Using a novel approach by calming the natural immune response to a multi-organ disease, CytoAgents' lead drug candidate, GP1681, is positioned to become the new best practice in medicine.

CytoAgents is successfully completing Phase I Human Clinical Trials. 

SAFE AND COST-EFFECTIVE TREATMENT FOR CRS

CytoAgents’ lead drug candidate, GP1681 is an oral, cost-effective, shelf-stable drug with an established safety record, making it an ideal stockpiling candidate.

 

The scientific consensus is building that overwhelming inflammation and severe illness is triggered by a phenomenon known as Cytokine Release Syndrome (CRS) or “Cytokine Storm,” an excessive immune response that attacks the body. The mortality, economic burden, and strain on the healthcare system as a consequence of CRS is devastating. 

CytoAgents' lead drug candidate modulates the body's immune response to reduce tissue damage caused by an excessive immune reaction. This approach decreases the tissue damage resulting from the excessive release of pro-inflammatory cytokines, known as the Cytokine Release Syndrome, which is induced by infectious and non-infectious diseases. Our approach to treatment focuses on reducing the destructive impact of the Cytokine Release Syndrome while leaving the necessary immune function intact.

CytoAgents' approach to therapy is independent of viral mutation and the development of viral resistance and therefore the therapeutic benefit applies broadly to future respiratory epidemics triggering Cytokine Release Syndrome.

ONCOLOGY: PREVENTING CAR-T CELL THERAPY ASSOCIATED CRS

CAR-T Induced Cytokine Release Syndrome CAR-T Therapy is a revolutionary, lifesaving approach to treating cancer. By modifying the patient’s own immune system and infusing these cells into the patient, the immune system’s response to the cancer is intensified, increasing the potential to cure the cancer. Current CAR-T commercial therapies require an extensive hospital stay primarily due to the risk of CRS. Roughly 70% of patients suffer from CRS, and at times this can be life threatening, requiring an ICU admission. The economic burden associated with the CAR-T therapy, the associated hospital admission and the complications of an ICU admission can approach $1M/patient.

CytoAgents looks to prevent this devastating side effect, eliminating hospitalization and improving outcomes.

COVID-19 AND RESPIRATORY EPIDEMICS

CytoAgents' lead drug candidate, GP1681, addresses a clear unmet need and will expand the category for therapy options available for the treatment of viral illnesses. The mechanism of action, fine-tuning the immune response by tamping down various cytokines, will enable the broad therapeutic benefit across a spectrum of illnesses associated with Cytokine Release Syndrome.

In addition to the catastrophic impact of COVID-19, the mortality rate of Acute Respiratory Distress Syndrome (ARDS) approaches 50% and lung injury associated with Vaping will amplify this unmet need. There continue to be more than 350K annual deaths from Influenza globally.

CytoAgents' approach to therapy is independent of viral mutation and the development of viral resistance and therefore the therapeutic benefit applies broadly to future respiratory epidemics triggering Cytokine Release Syndrome.

 

 
 

© 2021 by CytoAgents

  • LI-In-Bug